| Code | CSB-RA773595MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar of NS-101, targeting TAFA5 (also known as FAM19A5)—a secreted, chemokine-like neurokine that is predominantly detected in the central and peripheral nervous systems. TAFA5/FAM19A5 has been implicated in regulating neural circuit and synapse-related biology, and has been explored as a mechanistic node in synaptic dysfunction associated with neurodegenerative and sensorineural disorders.
NS-101 is an anti-FAM19A5 monoclonal antibody being developed to restore synapse function, with clinical evaluation reported in contexts such as sudden sensorineural hearing loss (SSNHL) and exploratory neurodegenerative indications. Preclinical studies have reported that NS101 treatment is associated with improved synaptic electrophysiology and cognitive readouts in Alzheimer’s disease models, supporting its use as a tool for probing TAFA5/FAM19A5-linked synapse biology. This biosimilar provides the antibody component alone, enabling researchers to investigate TAFA5/FAM19A5 biology, target engagement, and downstream synapse-related mechanisms in controlled experimental systems, independent of clinical formulation variables.
There are currently no reviews for this product.